Fierce Pharma
APRIL 25, 2024
After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin. | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.
MedCity News
APRIL 25, 2024
Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics. The post Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 25, 2024
Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co., and Johnson & Johnson about the high costs of their drugs, Sen. | Just a few months after laying into CEOs from Bristol Myers Squibb, Merck & Co. and Johnson & Johnson about the high costs of their drugs, Sen. Bernie Sanders, I-Vermont, is taking Novo Nordisk to task for allegedly turning its blockbuster GLP-1s Ozempic and Wegovy into “luxury goods.
MedCity News
APRIL 25, 2024
Walgreens announced that it is expanding its specialty pharmacy offerings. Experts think that this move could yield several strategic benefits, given the higher profit margins associated with specialty medications compared to traditional drugs. They also think Walgreens’ move could lead to greater competition, consolidation and innovation within the broader pharmacy industry.
Fierce Pharma
APRIL 25, 2024
Merck touted newly approved Winrevair and what the emergence of the potential blockbuster means for the company as it faces the LOE of Keytruda.
MedCity News
APRIL 25, 2024
People do not have to die waiting for a kidney. A VBC approach can lead to earlier identification of kidney disease and better management in its earlier stages. The post With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need? appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
APRIL 25, 2024
How health tech startups can successfully adapt the principles to their business ideas The post Examining the Usefulness of the Lean Startup Method in Building Health Tech Products appeared first on MedCity News.
Fierce Pharma
APRIL 25, 2024
Where innovation meets obstacles and the cost of drug development skyrockets, the key to unlocking success of groundbreaking products in the biopharma industry will rely heavily on strategic | Collaborative partnerships key to clearing the path for new biopharma products
Pharmaceutical Commerce
APRIL 25, 2024
The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.
Fierce Pharma
APRIL 25, 2024
Facing pressure from the Inflation Reduction Act (IRA) and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner, Ph.D., still says the Breyanzi-maker h | Facing pressure from the Inflation Reduction Act and falling sales for CAR-T therapy Abecma, Bristol Myers Squibb CEO Chris Boerner says the Beyenzi-maker had a "good start" with the first quarter.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharmaceutical Technology
APRIL 25, 2024
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
Fierce Pharma
APRIL 25, 2024
Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. | Novartis has started cutting ties with Chinese contractors amid a potential threat from the BIOSECURE Act. A depression drug candidate that Neurocrine licensed from Takeda succeeded in a phase 2 trial. AstraZeneca and Daiichi Sankyo's Enhertu is on the cusp of a key readout in HER2-low breast cancer.
European Pharmaceutical Review
APRIL 25, 2024
Research on the global pharmaceutical parenteral packaging market by InsightAce Analytic Pvt. Ltd. has predicted that the sector will value $18.85 billion by 2031. This is aligned with a CAGR of 4.47 percent between 2024 and 2031. Main drivers for the market were reported to be rising popularity of generics together with blockbuster and other small-molecule drugs going off-patent globally.
Fierce Pharma
APRIL 25, 2024
Joining a list that recently includes Pfizer, UCB and WuXi AppTec, Takeda Pharmaceuticals is the latest drugmaker to pull out of prominent industry lobbying group the Biotechnology Innovation Organ | The company opted not to renew its Biotechnology Innovation Organization (BIO) membership for its next fiscal year.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmaTimes
APRIL 25, 2024
The tool will help people find out about clinical trials for myeloma, MGUS, SMM and AL amyloidosis
Fierce Pharma
APRIL 25, 2024
Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. | Even as new Sanofi drugs like Beyfortus and Altuviiio come into their own, the French pharma’s immunology powerhouse Dupixent shows no signs of slowing down. In fact, Sanofi is already gearing up for the antibody’s potential debut in what CEO Paul Hudson dubbed the drug’s “next major growth pillar.
European Pharmaceutical Review
APRIL 25, 2024
A study has determined that for biologics subject to multiple stresses during bioprocessing and manufacturing , “exposure to air-liquid interfacial dilatational stress is the predominant mechanism impacting protein particle formation, [both] at the interface and in the bulk solution” Researchers established a “unique” set-up using a peristaltic pump and a Langmuir-Pockels trough to study the impact of hydrodynamic shear stress due to pumping and interfacial dilatational stress, on the form
Fierce Pharma
APRIL 25, 2024
Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. | This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Staff Writer Kevin Dunleavy are diving into our annual top pharma companies by revenue special report.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmaTimes
APRIL 25, 2024
X-linked Charcot-Marie-Tooth is the second most common form of the rare peripheral neuropathy disease
Fierce Pharma
APRIL 25, 2024
Navigating the Impact of the Inflation Reduction Act: Assessing Current Realities and Future Trajectory jpiatt Thu, 04/25/2024 - 14:30
MedCity News
APRIL 25, 2024
If you advise self-insured employers on healthcare benefits, your expert insights will help provide a comprehensive perspective of the state of healthcare benefits for employers in our second annual survey, the 2024 Benefit Consultant Sentiment THE INDEX. The post Which AI Applications Interest Your Employer Clients the Most? Where Will They Have the Greatest Impact?
Clarivate
APRIL 25, 2024
Sustainability has become increasingly critical for organizations to demonstrate their missions and address some of the world’s most pressing challenges. Much like digital transformation, driving sustainability requires organizations to transform every division of their business and integrate in the corporate strategy. As part of the 2030 Agenda for Sustainable Development, the United Nation (UN) has outlined seventeen Sustainable Development Goals (SDGs) as a blueprint for peace and prosperity
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
MedCity News
APRIL 25, 2024
Embedding patient financing options into the billing process presents a very clear solution for providers and patients to balance affordability and increase collectability. The post Debunking the Myths Around Patient Financing appeared first on MedCity News.
Pharmaceutical Commerce
APRIL 25, 2024
The latest news for pharma industry insiders.
Pharmaceutical Technology
APRIL 25, 2024
Merck has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany.
PharmaTech
APRIL 25, 2024
Continuous Manufacturing in pharmaceuticals can increase process understanding while overcoming disadvantages of batch manufacturing: slow and expensive development and tech transfer, plus inefficiencies, product loss, and human error in commercial manufacturing.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Referral MD
APRIL 25, 2024
Healthcare technology has reached new heights with ReferralMD’s game-changing Digital Front Door solution , powered by cutting-edge conversational AI. This innovative approach aims to reshape the patient experience and streamline administrative processes, marking a significant leap forward for healthcare providers and patients. ReferralMD sets itself apart in a competitive landscape by offering a comprehensive platform encompassing Digital Front Door , eConsults, Referral Management , Fax
PharmaTech
APRIL 25, 2024
Compliance and quality are not the same thing. While compliance means manufacturers demonstrate they meet regulatory requirements, quality is foundational to patients’ confidence in the safety and effectiveness of their medications.
PharmExec
APRIL 25, 2024
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address their specific healthcare needs
PharmaTech
APRIL 25, 2024
What innovations can help drug manufacturers and developers mitigate risks, reduce turnaround time, and increase success in early phase Cell & Gene therapy development?
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
244 
Let's personalize your content